Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Luca Biavati, MD, Anna Ferguson, BSN, RN, Carol Ann Huff, MD, Lakshmi Rudraraju, MS, Rachel Gittelman, Sarah Johnson, Catherine Sanders, Syed Abbas Ali, MD, Kimberly Noonan, PhD MPH, Ivan M. Borrello, MD

Blood (2019) 134 (Supplement_1): 1895.

https://doi.org/10.1182/blood-2019-128430

Published: 2019

Journal Articles

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Blood (2019) 134 (Supplement_1): 1872.

https://doi.org/10.1182/blood-2019-122908

Published: 2019

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Elizabeth K. O'Donnell, MD, Jacob P. Laubach, MD, Andrew J. Yee, MD, Robert Redd, Carol Ann Huff, MD, Frank Basile, MD, Philip M. Wade, MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L. Schlossman, MD, Jill N. Burke, NP, Cynthia C. Harrington, NP, Kathleen J. Lively, RN, Hannah Lyons, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 3178.

https://doi.org/10.1182/blood-2019-128000

Published: 2019

Journal Articles

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Blood (2019) 134 (Supplement_1): 3140.

https://doi.org/10.1182/blood-2019-129038

Published: 2019

Journal Articles

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Kimberly A Noonan, PhD MPH, Lakshmi Rudraraju, MS, Valentina Hoyos, MD, Eric Lutz, PhD, Ivan Borrello, MD

Blood (2016) 128 (22): 4552.

https://doi.org/10.1182/blood.V128.22.4552.4552

Published: 2016

Journal Articles

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Kimberly Noonan, PhD MPH, Carol Ann Huff, Amy Sidorski, NP, Anna Ferguson, RN, Lakshmi Rudraraju, MS, Andrea Casildo, BS, Ivan Borrello, MD

Blood (2014) 124 (21): 2137.

https://doi.org/10.1182/blood.V124.21.2137.2137

Published: 2014

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Elizabeth O'Donnell, MD, Jacob P. Laubach, MD, Andrew J Yee, MD, Carol Ann Huff, MD, Frank Basile, MD, Philip M. Wade, MD, Claudia E. Paba-Prada, MD, Irene M. Ghobrial, MD, Robert L Schlossman, MD, Nicole Couture, RN, Lauren Doherty, Hannah Lyons, RN, Caroline English, Nikhil Munshi, Kenneth C. Anderson, Paul G. Richardson, MD, Noopur Raje, MD

Blood (2014) 124 (21): 3454.

https://doi.org/10.1182/blood.V124.21.3454.3454

Published: 2014

Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4039.

https://doi.org/10.1182/blood.V120.21.4039.4039

Published: 2012

Journal Articles

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

Carol Ann Huff, M.D., Quiju Wang, MS, Ashraf Z. Badros, MD, Richard J. Jones, Anita Reddy, PhD, Kevin Nishimoto, PhD, Monic J. Stuart, MD, MPH, Stephen M Kelsey, MD, William Matsui, MD

Blood (2012) 120 (21): 4898.

https://doi.org/10.1182/blood.V120.21.4898.4898

Published: 2012

Journal Articles

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

Carol A. Huff, MD, Swaminathan Padmanabhan, MD, Kevin R. Kelly, MD, George Somlo, MD, Luis Camacho, MD, MPH, Jeffrey Zonder, MD, Bruce Fischer, MD, Lixin Lang, Steven Zhang, Toni Gestone, Kelly L. Bennett

Blood (2011) 118 (21): 3993.

https://doi.org/10.1182/blood.V118.21.3993.3993

Published: 2011

Journal Articles

A Novel Activating JAK2 Mutation, JAK2R564Q, Causes Familial Essential Thrombocytosis (fET) Via Mechanisms Distinct From JAK2V617F

Leah Etheridge, PhD, Lana M Corbo, BS, Kenneth Kaushansky, MD, Edward Chan, MD, Ian S Hitchcock, PhD

Blood (2011) 118 (21): 123.

https://doi.org/10.1182/blood.V118.21.123.123

Published: 2011

Journal Articles

Origin of the Myeloma Stem Cell

William Matsui, MD

Blood (2010) 116 (21): SCI-4.

https://doi.org/10.1182/blood.V116.21.SCI-4.SCI-4

Published: 2010

Journal Articles

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Nilanjan Ghosh, Anna Ferguson, RN, Xiaobu Ye, Carol A. Huff, MD, Ivan M. Borrello, MD

Blood (2009) 114 (22): 2867.

https://doi.org/10.1182/blood.V114.22.2867.2867

Published: 2009

Journal Articles

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

Kimberly Ann Noonan, MPH, BS, Anna Ferguson, RN, Amy Emerling, Lakshmi Rudraraju, M.S., Carol A. Huff, MD, Peter H Schafer, Ivan M. Borrello, MD

Blood (2009) 114 (22): 1864.

https://doi.org/10.1182/blood.V114.22.1864.1864

Published: 2009

NARROW

An Allogeneic GM-CSF-Based Vaccine in Combination with Lenalidomide Induces Durable Remissions and Sustained Immunological Responses in Multiple Myeloma

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Persistence of Non Gene-Modified Adoptively Transferred Marrow Infiltrating Lymphocytes (MILs) More Than Five Years Post Transfer

Lenalidomide Immunomodulation with an Allogeneic Myeloma GVAX in a Near Complete Remission Induces Durable Clinical Remissions

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial

A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma,

A Novel Activating JAK2 Mutation, JAK2R564Q, Causes Familial Essential Thrombocytosis (fET) Via Mechanisms Distinct From JAK2V617F

Origin of the Myeloma Stem Cell

Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma.

Lenalidomide Augments Immune Responses to Prevnar Vaccination in Relapsed Myeloma Patients: Implications for Cancer and Infectious Vaccines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only